Veradermics (NYSE:MANE) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Veradermics (NYSE:MANE) from a sell rating to a hold rating in a research note published on Saturday.

Other analysts have also issued reports about the stock. Leerink Partners boosted their target price on shares of Veradermics from $75.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, April 22nd. Weiss Ratings initiated coverage on shares of Veradermics in a research note on Tuesday, May 26th. They set a “sell (d+)” rating on the stock. Lifesci Capital initiated coverage on shares of Veradermics in a research report on Tuesday, June 16th. They set an “outperform” rating and a $135.00 price objective for the company. UBS Group set a $170.00 price objective on Veradermics in a research note on Wednesday, July 15th. Finally, Needham & Company LLC raised their target price on Veradermics from $136.00 to $164.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $153.00.

Veradermics Price Performance

Shares of NYSE:MANE opened at $105.05 on Friday. The stock has a 50-day moving average price of $108.02. The stock has a market capitalization of $4.39 billion and a PE ratio of -79.58. Veradermics has a 52-week low of $32.00 and a 52-week high of $131.24.

Veradermics (NYSE:MANE) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.76).

Veradermics Company Profile

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.